How should centrally mediated abdominal pain be managed?

Management of Centrally Mediated Abdominal Pain

Centrally mediated abdominal pain should be managed with neuromodulators (tricyclic antidepressants as first-line, SNRIs/SSRIs as alternatives) combined with brain-gut behavioral therapies, while strictly avoiding opioids. 1

Core Treatment Framework

Establish the Therapeutic Foundation

The patient-provider relationship is not optional—it is the treatment platform. You must explain pain pathogenesis using neuroscience language: the pain originates from altered central nervous system processing, not ongoing tissue damage. Frame this as visceral hypersensitivity and central sensitization, not psychological weakness. 1

Critical pitfall to avoid: Never suggest the pain "isn't real" or is "all in your head" in a dismissive way. Instead, emphasize that pain processed in the brain is still genuine pain, but requires brain-targeted treatments rather than gut-targeted ones.

Pharmacologic Management Algorithm

First-line neuromodulators:

• Tricyclic antidepressants (TCAs) are the most effective pharmacologic option 2, 3, 4
  • Start amitriptyline or desipramine at 10-25 mg at bedtime
  • Titrate by 10-25 mg every 1-2 weeks based on response
  • Target dose: 50-75 mg (lower than antidepressant dosing)
  • Pain relief occurs faster and at lower doses than when treating depression
  • Side effects: dry mouth, constipation (may benefit IBS-D), sedation, dizziness

Second-line alternatives:

• Duloxetine (SNRI) shows efficacy in chronic continuous abdominal pain 5, 4

  • Start 30 mg daily, increase to 60 mg after 1-2 weeks
  • Preferred when comorbid anxiety/depression exists
  • Better tolerated than TCAs with lower anticholinergic burden

• SSRIs (paroxetine, citalopram, fluoxetine) 2, 6, 3

  • Less evidence for pain relief than TCAs
  • Use when mood/anxiety disorders predominate
  • Start at standard antidepressant doses if treating psychiatric comorbidity

Combination therapy is superior to monotherapy for refractory cases 7, 4. Consider adding a second neuromodulator from a different class, but monitor for serotonin syndrome.

Non-Pharmacologic Therapies (Not Optional)

Introduce these early, not as a last resort 1, 8:

Cognitive Behavioral Therapy (CBT):

• Targets pain catastrophizing, maladaptive thoughts, and avoidance behaviors
• 4-12 sessions with a GI psychologist
• Most effective when patients recognize thought-pain connections
• Reduces abdominal pain, improves coping, decreases healthcare utilization 2, 8

Gut-Directed Hypnotherapy:

• 7-12 sessions with trained clinician or internet-based programs
• Particularly effective for visceral hypersensitivity and somatization
• Contraindicated in severe PTSD 8, 3

When to refer for psychological therapy:

• Pain persists after 12 months of drug treatment (can refer earlier based on severity and patient preference) 7
• Comorbid psychiatric disorders present
• History of trauma/abuse
• High pain catastrophizing or poor coping evident

What to Absolutely Avoid

Opioids are contraindicated 1, 9, 7:

• Do not prescribe opioids for centrally mediated GI pain
• If patients present already on opioids, work toward discontinuation through multidisciplinary collaboration
• Opioids worsen outcomes, cause narcotic bowel syndrome (worsening pain despite escalating doses), increase infection risk, and invalidate motility testing
• Opioid use is associated with allodynia (81% in one cohort) 4

Repeated surgery worsens outcomes:

• In one cohort, 68% underwent surgical interventions—surgery resolved pain in 0% and worsened pain in 35% 4
• Surgery is appropriate only for structural/obstructive pathology, not centrally mediated pain

Anxiolytics are not recommended:

• Weak treatment effects, dependence risk, drug interactions 2

Distinguishing Centrally Mediated from Visceral Pain

Look for these features suggesting central mechanisms 1:

• Constant pain (not meal-related or bowel movement-related)
• Allodynia (nonpainful stimuli causing pain—present in 81% of chronic continuous abdominal pain) 4
• Pain descriptors: "unbearable," "ripping," "tearing" suggest emotional reactivity networks
• Lack of correlation between pain severity and structural findings
• Comorbid conditions: fibromyalgia, chronic headaches, anxiety, depression
• Early life adversity or trauma history
• Pain catastrophizing behaviors

Rome IV criteria for Centrally Mediated Abdominal Pain Syndrome (CAPS) require continuous or nearly continuous abdominal pain for ≥6 months, but recognize that 50% may have physiological exacerbations that don't preclude central origin 4.

Treatment Response Monitoring

• Assess pain reduction, functional improvement, and quality of life—not just pain scores
• Neuromodulator effects on pain occur within 2-4 weeks at therapeutic doses
• If no response after 8-12 weeks at adequate doses, switch to alternative neuromodulator class
• Combination therapy should be considered before declaring treatment failure 7, 4

Refractory Cases

For severe or refractory symptoms 7:

• Review diagnosis—consider targeted investigation to exclude missed organic pathology
• Ensure centrally mediated pain diagnosis is secure (not narcotic bowel syndrome, small intestinal dysmotility, or other severe functional GI disorders)
• Refer to multidisciplinary chronic pain team
• Consider augmentation with combination neuromodulators (monitor for serotonin syndrome)
• Intrathecal drug delivery has emerging evidence in highly selected cases after excluding centrally mediated mechanisms 10

The key principle: Match treatment to pain mechanism. Visceral/nociceptive pain responds to peripheral interventions; centrally mediated pain requires central neuromodulation and behavioral therapies. Attempting to treat central pain with repeated procedures, imaging, or opioids causes iatrogenic harm.